Los Angeles Capital Management
VKTX icon

Los Angeles Capital Management’s Viking Therapeutics VKTX Stock Holding History

Los Angeles Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15K Hold
461
– – ﹤0.01% 1829
2025
Q4 		$17.6K Buy
+461
New +$16.3K ﹤0.01% 1914
2025
Q1 		– Sell
-5,681
Closed -$229K – 1237
2024
Q4 		$229K Sell
5,681
-5,267
-48% -$300K ﹤0.01% 1016
2024
Q3 		$693K Sell
10,948
-1,330
-11% -$78K ﹤0.01% 773
2024
Q2 		$651K Buy
12,278
+372
+3% +$24.4K ﹤0.01% 785
2024
Q1 		$976K Buy
+11,906
New +$530K ﹤0.01% 695

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Los Angeles Capital Management's VKTX Position: Q1 2026 in Review

Los Angeles Capital Management held its Viking Therapeutics (VKTX) position steady in Q1 2026 at 461 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1829.

Los Angeles Capital Management first reported a position in VKTX in Q1 2024 and has held it in 6 quarters since. The position peaked at $976K in Q1 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Los Angeles Capital Management held 461 shares of Viking Therapeutics worth $15K as of Q1 2026.
  • Los Angeles Capital Management left its Viking Therapeutics share count unchanged in Q1 2026.
  • Viking Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1829 holding.
  • Los Angeles Capital Management first reported a position in Viking Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • Los Angeles Capital Management's Viking Therapeutics position peaked at $976K in Q1 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.